ScholarIQanswers from OpenAlex & ORCID
Ralf Gutzmer
ResearcherPublications, citations & collaboration network
Ralf Gutzmer is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Ralf Gutzmer have?
ScholarIQindexed works
Ralf Gutzmer has 753 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ralf Gutzmer have?
ScholarIQcitation count
Ralf Gutzmer has 41,323 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Ralf Gutzmer?
ScholarIQh-index
Ralf Gutzmer has an h-index of 83 in OpenAlex.
What is the i10-index of Ralf Gutzmer?
ScholarIQi10-index
Ralf Gutzmer has an i10-index of 333 in OpenAlex.
What is the ORCID of Ralf Gutzmer?
ScholarIQorcid
The ORCID for Ralf Gutzmer is on the source record.
What is the OpenAlex record for Ralf Gutzmer?
ScholarIQopenalex
The OpenAlex for Ralf Gutzmer is on the source record.
What are the most-cited papers on Ralf Gutzmer?
ScholarIQmost cited works
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen, Diana Miao, Bastian Schilling, Sachet A. Shukla, Christian U. Blank, Lisa Zimmer, Antje Sucker, Uwe Hillen, Marnix H. Geukes Foppen, Simone M. Goldinger, Jochen Utikal, Jessica C. Hassel, Benjamin Weide, Katharina C. Kaehler, Carmen Loquai, Peter Mohr, Ralf Gutzmer, Reinhard Dummer, Stacey Gabriel, Catherine J. Wu, Dirk Schadendorf, Levi A. Garraway
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Höeller, Nikhil I. Khushalani, Wilson H. Miller, Christopher D. Lao, Gerald P. Linette, L. Thomas, Paul Lorigan, Kenneth F. Grossmann, Jessica C. Hassel, Michele Maio, Mario Sznol, Paolo A. Ascierto, Peter Mohr, Bartosz Chmielowski, Alan H. Bryce, Inge Marie Svane, Jean‐Jacques Grob, Angela M. Krackhardt, Christine E. Horak, Alexandre Lambert, Arvin Yang, James Larkin
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Michele Maio, Alfonsus Johannes Maria van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Nageatte Ibrahim, Sandrine Marréaud, Alexander C. J. van Akkooi, Stefan Suciu, Caroline Robert
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu, Bastian Schilling, Derek Liu, Antje Sucker, Elisabeth Livingstone, Livnat Jerby‐Arnon, Lisa Zimmer, Ralf Gutzmer, Imke Satzger, Carmen Loquai, Stephan Grabbe, Natalie I. Vokes, Claire A. Margolis, Jake R. Conway, Meng Xiao He, Haitham Elmarakeby, Felix Dietlein, Diana Miao, Adam Tracy, Helen Gogas, Simone M. Goldinger, Jochen Utikal, Christian U. Blank, Ricarda Rauschenberg, Dagmar von Bubnoff, Angela M. Krackhardt, Benjamin Weide, Sebastian Haferkamp, Felix Kiecker, Ben Izar, Levi A. Garraway, Aviv Regev, Keith T. Flaherty, Annette Paschen, Eliezer M. Van Allen, Dirk Schadendorf
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
Michael R. Migden, Alexander Guminski, Ralf Gutzmer, Luc Dirix, Karl D. Lewis, P. Combemale, R. M. Herd, Ragini R. Kudchadkar, Uwe Trefzer, Sven Gogov, Céline Pallaud, Tingting Yi, Manisha Mone, Martin Kaatz, Carmen Loquai, Alexander Stratigos, H. J. Schulze, Ruth Plummer, Anne Lynn S. Chang, Frank Cornélis, John T. Lear, Dalila Sellami, Reinhard Dummer